Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation – Data from RACE 3 - 16/08/20

Doi : 10.1016/j.ahj.2019.12.005

Bao-Oanh Nguyen, MD ^a, Michiel Rienstra, MD, PhD ^a, Anne H. Hobbelt, MD, PhD ^a, Jan G.P. Tijssen, PhD ^b, Marcelle D. Smit, MD, PhD ^c, Robert G. Tieleman, MD, PhD ^c, Bastiaan Geelhoed, PhD ^a, Dirk J. Van Veldhuisen, MD, PhD ^a, Harry J.G.M. Crijns, MD, PhD ^d, Isabelle C. Van Gelder, MD, PhD ^a,^{^⁎}
; for the
RACE 3 Investigators
^a Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
^b Clinical epidemiology and biostatistics, Academic Medical Center of Amsterdam, Amsterdam, The Netherlands
^c Martini Hospital, Groningen, The Netherlands
^d Maastricht University Medical Center+ and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands

^⁎Reprint requests: Isabelle C. Van Gelder, MD, PhD, Department of Cardiology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. Tel.: +31 50 3611327; fax: +31 50 3614391.Department of CardiologyUniversity Medical Center Groningen, University of GroningenP.O. Box 30.001Groningen9700 RBThe Netherlands

Abstract

Atrial fibrillation (AF) is a progressive disease, and maintenance of sinus rhythm is cumbersome. In this analysis of the Routine versus Aggressive risk factor driven upstream rhythm Control for prevention of Early atrial fibrillation in heart failure (RACE 3) trial we aimed to determine whether optimal treatment of underlying conditions of AF improves maintenance of sinus rhythm in patients with persistent AF and moderate heart failure (HF). Our data showed that optimal treatment of blood pressure, LDL-cholesterol and heart failure was associated with an increase in sinus rhythm maintenance compared to conventional therapy (87% versus 63%, P = .002, respectively).

Le texte complet de cet article est disponible en PDF.

Plan

☆

Trial Registration number: Clinicaltrials.gov NCT00877643

☆☆

Funding: The study is supported by the Netherlands Heart Foundation (Grant 2008B035).
Unrestricted grants from AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Medtronic, Sanofi-Aventis, St Jude Medical paid to the Netherlands Heart Institute. Dr Tieleman reports grants and personal fees from Bayer, Bristol-Myers-Squibb, Pfizer, and Daiichi-Sankyo. All other authors have no competing interests.

Export

Vol 226

P. 235-239 - août 2020 Retour au numéro

Article précédent

Use and outcomes of wearable cardioverter-defibrillators in a large integrated academic health system
Peter A. Kahn, Jadry Gruen, Alex Thomas, Tariq Ahmad, Nihar R. Desai

| Article suivant

Does really central venous pressure affect the risk of diuretic-associated acute kidney injury after cardiac surgery?
Ian McCoy, Maria Montez-Rath, Glenn Chertow, Tara Chang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation – Data from RACE 3 - 16/08/20

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL